PEStore

Venture Capital

Omega Funds

Omega Funds backs early-stage and high-growth companies, typically pre-profit, from Boston, United States. It states a focus on healthcare & life sciences.

Disclosed holdings117
Earliest stated investment
HeadquartersBoston, United States
Largest single fundNot stated

Stated investment criteria

What Omega Funds says it buys

Read from Omega Funds’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.

OfficesBoston1

A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. Nothing here is a commitment by Omega Funds to consider any particular business, and nothing on this page is represented as being for sale.

Regulatory record

How Omega Funds is registered

From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.

Adviser statusSEC registered
Regulatory assets under management$1.7bn
Employees21
Private funds advised5 · $914m gross
SEC adviser numberCRD 157753

Portfolio

Disclosed holdings

Companies Omega Funds lists on its own website. No investment years are published.

CompanyInvestedYears heldRecorded transaction
Achaogen
Acrux
Adagio Therapeutics
Aerium Therapeutics
Alleviant Medical
Alpine Immune
Alumis Inc.
Alveus Therapeutics
Amunix
Anaconda Biomed
Andrew Alliance
Anjarium BioSciences
Antares Therapeutics
Aquarius
Arcutis
Artios
Atea
BBOT
Beam Therapeutics
Beta Bionics
Bicara Therapeutics
Bioinvent International
CDR-Life
CatalYm
Checkmate
Chord Therapeutics
Cidara Therapeutics
CinCor Pharma
CropDesign
Cymabay Therapeutics
DBV Technologies
Develogen
Dicerna
EDITAS Medicine
ESSA
Egalet
Elbion/Biotie
Enanta
Endeavor BioMedicines
Epigenomics
Etherna
Evotec
Exenta
ExonHit
EyeBio
First Wave
FoRx Therapeutics
Gelsight
Gossamer Bio
Hybrigenics
Hydrocision
IFM Therapeutics
Imagene
Imago BioSciences
Immunic Therapeutics
Immunocore
Intarcia Therapeutics
JenaValve Technology
Jerini
Juno Therapeutics
Kestra Medical Technologies
Kezar Life Sciences
Kronos Bio
Kuros Biosciences
Median Technologies
Micromet
Middlebrook
Momenta
NRG Therapeutics
Nabriva
National Resilience
Neurotech
Neurovision
Newron
Newsummit Biopharma
Nuvation Bio
ObsEva
Ousia Pharma
Oxagen
Paion
Paratek
Phoqus
Pieris
Prevail Therapeutics
Protego Bio
Proteon Therapeutics
Rectify Pharma
Replimune
Rib-X
Sail Biomedicines
Sana
Santaris Pharma
Scibase Holdings
Senti Biosciences
Show + Tell
Sienna
SoniVie
Sosei Group
Spinevision
Spiro Medical
Spruce BioSciences
Synthekine
Syros
Telesta Therapeutics
Third Arc Bio
Translate Bio
Trevi Therapeutics
Upstream Bio
Vaderis Therapeutics
Vanqua Bio
Visterra
Vivostat
Windward Bio
XII Medical
Xtuit
enGene
nChroma Bio

Compiled from Omega Funds’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.

Valuation context

Transaction values in Healthcare & Life Sciences

What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.

Median consideration$110m
Middle 50%$30m-$318m
Revenue multiple2.8×
EBITDA multiple12.5×

The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.

For owners

Own a healthcare & life sciences business?

The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.

Request a confidential valuation

For investors

Is this Omega Funds?

Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.

Claim or correct this profile

Targeted buyer search

Which hundred of these would actually buy your business?

A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.

See how it works

Comparable investors

Similar mandates

Other venture capital investors active in healthcare & life sciences.